LORAZEPAM TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

LORAZEPAM

Saatavilla:

SIVEM PHARMACEUTICALS ULC

ATC-koodi:

N05BA06

INN (Kansainvälinen yleisnimi):

LORAZEPAM

Annos:

2MG

Lääkemuoto:

TABLET

Koostumus:

LORAZEPAM 2MG

Antoreitti:

ORAL

Kpl paketissa:

100/1000

Prescription tyyppi:

Targeted (CDSA IV)

Terapeuttinen alue:

BENZODIAZEPINES

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0110731002; AHFS:

Valtuutuksen tilan:

CANCELLED POST MARKET

Valtuutus päivämäärä:

2016-09-08

Valmisteyhteenveto

PRODUCT MONOGRAPH
LORAZEPAM
LORAZEPAM TABLETS USP
0.5 MG, 1 MG AND 2 MG
ANXIOLYTIC-SEDATIVE
SIVEM PHARMACEUTICALS ULC
4705 DOBRIN STREET
SAINT-LAURENT, QUÉBEC
H4R 2P7
DATE OF PREPARATION: AUGUST 20, 2014
CONTROL NO. : 176952
Lorazepam Product Monograph
Page 2 of 24
TABLE OF CONTENTS
PRESCRIBING INFORMATION
.............................................................................................
1
ACTIONS AND CLINICAL PHARMACOLOGY
.......................................................................
3
INDICATIONS AND CLINICAL USE
.......................................................................................
6
CONTRAINDICATIONS
..........................................................................................................
6
WARNINGS
...........................................................................................................................
6
PRECAUTIONS
......................................................................................................................
7
DRUG INTERACTIONS
..........................................................................................................
9
ADVERSE REACTIONS
.......................................................................................................
10
SYMPTOMS AND TREATMENT OF OVERDOSE
............................................................... 11
DOSAGE AND ADMINISTRATION
.......................................................................................
11
AVAILABILITY OF DOSAGE FORMS
..................................................................................
12
PHARMACEUTICAL INFORMATION
...................................................................................
13
PHARMACOLOGY................................................................................................................
14
TOXICOLOGY.......................................................................................................................
16
REFERENCES
.................................................